Clinical Trial Update: Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tislelizumab in combination with lenvatinib as perioperative therapy for resectable hepatocellular carcinoma; status not reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Resectable Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN